By


Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

See more here

By


Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap

See more here

By


Scripps Health and UT Health San Antonio purchase Oncora’s software to improve physician documentation and enhance personalized cancer care

See more here

By


Melior Announces Substantial Additions to Its Management and Scientific Team 

• Dr. Ken Kilgore joins Melior as VP of Scientific Operations

• Dr. Hongyan Li joins Melior as Director of Oncology

• Dr. Vivian Cong rises to VP of Research & Development

See more here

By


WellTrackONE Corporation releases Targeted Risk Adjustment Coding system (TRAC)

TRAC will help with HCC RAF scores, lost revenue opportunities and avoidance of RAC/RADV audit penalties

See more here

By


Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund

See more here

By


Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

– Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application –

– Immunome Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial –

– Ongoing Progress on Oncology Pipeline, Including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint –

See more here

By


Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing

Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen, Ph.D., as CSO and Elizabeth White, Ph.D., as CBO and SVP of Operations

Reported topline preclinical data demonstrating successful cardiac transduction with REN-001 delivered via local infusion at a low vector dose in a pilot pig study

Significant progress made across key ongoing REN-001 IND-enabling studies

IND submission for REN-001 is expected in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM anticipated to follow

See more here

By


Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

See more here

By


KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics

Novel Approach to Treat Late-Stage and Metastatic Cancers

See more here